Marksans Pharma gets EIR from USFDA for its Goa facility

Drug firm Marksans Pharma Thursday said it has received Establishment Inspection Report (EIR) from the US health regulator for its Goa facility. The company has received EIR from the United States Food and Drug Administration (USFDA) in respect of inspection of its Goa facility carried out from February 25 to March 6, 2019, Marksans Pharma said in a filing to the BSE.

The Mumbai-headquartered firm is engaged in research, manufacturing and marketing of generic pharmaceutical formulations in the global markets. Shares of Marksans Pharma Thursday ended at Rs 22.70 per scrip on the BSE, up 3.89 per cent from its previous close.

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)